UK trial marks progress for Biota's rhinovirus product
This article was originally published in Scrip
Executive Summary
The Australian firm Biota Holdings has begun an early Phase II clinical trial in the UK with BTA798, its lead oral inhibitor of the human rhinovirus (HRV).